In summary, we speculate that functionalchanges (i.e., EAAT2 lossand decreased glutamate uptake capacity) may precede astrocytic morphologicalalterations (e.g., GFAP increased levels) and deposition of insolubleAβ aggregates in the early stages of AD. This evidence concerns the gene SLC1A2 and Alzheimer disease.